Hydroxychloroquine and chloroquine have been proposed as treatments for coronavirus disease 2019 (Covid-19) on the basis of in vitro activity and data from
A clinical trial to evaluate the safety and effectiveness of hydroxychloroquine for the treatment of adults hospitalized with coronavirus disease 2019 (COVID-19) has begun, with the first
Hydroxychloroquine (HCQ) is a drug that accumulates in endosomes and decreases their acidity, which disrupts their function
They noted that chronic fatigue diagnoses continued in the 18 months after COVID-19 detection, suggesting a “persistent effect” but
Among patients hospitalized with mild-to-moderate Covid-19, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at
We determined the